Quantum Biopharma (NASDAQ:QNTM) Releases Earnings Results, Misses Estimates By $0.06 EPS

Quantum Biopharma (NASDAQ:QNTM) posted its quarterly earnings results on Thursday. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.06), Zacks reports.

Quantum Biopharma Stock Performance

Shares of Quantum Biopharma stock traded down $0.25 during midday trading on Thursday, hitting $3.23. 223,249 shares of the company traded hands, compared to its average volume of 298,039. The firm’s fifty day moving average price is $3.46 and its 200-day moving average price is $4.08. The stock has a market cap of $20.67 million, a price-to-earnings ratio of -0.39 and a beta of 0.45. Quantum Biopharma has a 12 month low of $2.07 and a 12 month high of $23.66.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Quantum Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Weiss Ratings downgraded shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Quantum Biopharma stock. Virtu Financial LLC purchased a new position in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,406 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned about 0.27% of Quantum Biopharma at the end of the most recent quarter. 1.24% of the stock is currently owned by institutional investors.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.